References

  1. 1.Song P, Zha M, Yang Q, et al. The prevalence of adult attention-deficit hyperactivity disorder: a global systematic review and meta-analysis. J Glob Health. 2021;11:04009.
  2. 2.Williams OC, Prasad S, McCrary A, et al. Adult attention deficit hyperactivity disorder: a comprehensive review. Ann Med Surg (Lond). 2023;85(5):1802-1810.
  3. 3.Attoe DE, Climie EA. Miss. Diagnosis: a systematic review of ADHD in adult women. J Atten Disord. 2023;27(7):645-657.
  4. 4.Ohan JL, Visser TA. Why is there a gender gap in children presenting for attention deficit/hyperactivity disorder services? J Clin Child Adolesc Psychol. 2009;38(5):650-660.
  5. 5.Arnsten AFT. Guanfacine’s mechanism of action in treating prefrontal cortical disorders: successful translation across species. Neurobiol Learn Mem. 2020;176:107327.
  6. 6.Choi WS, Woo YS, Wang SM, et al. The prevalence of psychiatric comorbidities in adult ADHD compared with non-ADHD populations: a systematic literature review. PLoS One. 2022;17(11):e0277175.
  7. 7.Barbuti M, Maiello M, Spera V, et al. Challenges of treating ADHD with comorbid substance use disorder: considerations for the clinician. J Clin Med. 2023;12(9):3096.
  8. 8.Diagnostic and Statistical Manual of Mental Disorders, 5th ed., text revision. American Psychiatric Association; 2022.
  9. 9.Kessler RC, Adler L, Ames M, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005;35(2):245-256.
  10. 10.Drechsler R, Brem S, Brandeis D, et al. ADHD: current concepts and treatments in children and adolescents. Neuropediatrics. 2020;51(5):315-335.
  11. 11.Ben-Dor Cohen M, Eldar E, Maeir A, et al. Emotional dysregulation and health related quality of life in young adults with ADHD: a cross sectional study. Health Qual Life Outcomes. 2021;19(1):270.
  12. 12.Kamradt JM, Eadeh HM, Nikolas MA. Sluggish cognitive tempo as a transdiagnostic link between adult ADHD and internalizing symptoms. J Psychopathol Behav Assess. 2022;44(3):699-712.
  13. 13.Philipsen A, Jans T, Graf E, et al. Effects of group psychotherapy, individual counseling, methylphenidate, and placebo in the treatment of adult attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(12):1199-1210.
  14. 14.Ostinelli EG, Schulze M, Zangani C, et al. Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. Lancet Psychiatry. 2025;12(1):32-43.
  15. 15.Cortese S. Evidence-based prescribing of medications for ADHD: where are we in 2023? Expert Opin Pharmacother. 2023;24(4):425-434.
  16. 16.Macaluso M, Johnston C. Handbook of Practical Psychopharmacology. American Psychiatric Association Publishing; 2025.
  17. 17.National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. https://www.nice.org.uk/guidance/ng87
  18. 18.Nimmo-Smith V, Merwood A, Hank D, et al. Non-pharmacological interventions for adult ADHD: a systematic review. Psychol Med. 2020;50(4):529-541.
  19. 19.Mongia M, Hechtman L. Cognitive behavior therapy for adults with attention-deficit/hyperactivity disorder: a review of recent randomized controlled trials. Curr Psychiatry Rep. 2012;14(5):561-567.
  20. 20.Li L, Zhu N, Zhang L, et al. ADHD pharmacotherapy and mortality in individuals with ADHD. JAMA. 2024;331(10):850-860.
  1. 1.American Psychological Association. Trauma. https://www.apa.org/topics/trauma
  2. 2.Diagnostic and Statistical Manual of Mental Disorders, 5th ed., text revision. American Psychiatric Association; 2022.
  3. 3.Goldstein RB, Smith SM, Chou SP, et al. The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Soc Psychiatry Psychiatr Epidemiol. 2016;51(8):1137-1148.
  4. 4.Bassett D, Buchwald D, Manson S. Posttraumatic stress disorder and symptoms among American Indians and Alaska Natives: a review of the literature. Soc Psychiatry Psychiatr Epidemiol. 2014;49(3):417-433.
  5. 5.Sartor Z, Kelley L, Laschober R. Posttraumatic stress disorder: evaluation and treatment. Am Fam Physician. 2023;107(3):273-281.
  6. 6.Al Jowf GI, Ahmed ZT, Reijnders RA, et al. To predict, prevent, and manage post-traumatic stress disorder (PTSD): a review of pathophysiology, treatment, and biomarkers. Int J Mol Sci. 2023;24(6):5238.
  7. 7.Miao XR, Chen QB, Wei K, et al. Posttraumatic stress disorder: from diagnosis to prevention. Mil Med Res. 2018;5(1):32.
  8. 8.US Department of Veterans Affairs. PTSD: National Center for PTSD. https://www.ptsd.va.gov/professional/treat/essentials/complex_ptsd.asp
  9. 9.Guzman Torres E, Krause-Utz A, Sack M. Predictors of complex PTSD: the role of trauma characteristics, dissociation, and comorbid psychopathology. Borderline Personal Disord Emot Dysregul. 2023;10(1):1.
  10. 10.U.S. Department of Veterans Affairs. VA/DoD clinical practice guidelines. Management of posttraumatic stress disorder and acute stress disorder 2023. https://www.healthquality.va.gov/guidelines/MH/ptsd
  11. 11.Bisson JI, Roberts NP, Andrew M, et al. Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults. Cochrane Database Syst Rev. 2013;2013(12):CD003388.
  12. 12.Asmundson GJG, Thorisdottir AS, Roden-Foreman JW, et al. A meta-analytic review of cognitive processing therapy for adults with posttraumatic stress disorder. Cogn Behav Ther. 2019;48(1):1-14.
  13. 13.Schrader C, Ross A. A review of PTSD and current treatment strategies. Mo Med. 2021;118(6):546-551.
  14. 14.Scelles C, Bulnes LC. EMDR as treatment option for conditions other than PTSD: a systematic review. Front Psychol. 2021;12:644369.
  15. 15.Post-traumatic Stress Disorder. NICE guideline. National Institute for Health and Care Excellence; 2018.
  16. 16.Guina J, Rossetter SR, DeRhodes BJ, et al. Benzodiazepines for PTSD: a systematic review and meta-analysis. J Psychiatr Pract. 2015;21(4):281-303.
  17. 17.Wolfgang AS, Hoge CW. Cannabis and cannabinoids for pain and posttraumatic stress disorder in military personnel and veterans. JAMA Psychiatry. 2023;80(9):869-870.
  18. 18.Kline AC, Cooper AA, Rytwinksi NK, et al. Long-term efficacy of psychotherapy for posttraumatic stress disorder: a meta-analysis of randomized controlled trials. Clin Psychol Rev. 2018;59:30-40.
  19. 19.Salas J, Gebauer S, Gillis A, et al. Increased smoking cessation among veterans with large decreases in posttraumatic stress disorder severity. Nicotine Tob Res. 2022;24(2):178-185.
  20. 20.van den Berk Clark C, Kansara V, Fedorova M, et al. How does PTSD treatment affect cardiovascular, diabetes and metabolic disease risk factors and outcomes? A systematic review. J Psychosom Res. 2022;157:110793.
  1. 1.Diagnostic and Statistical Manual of Mental Disorders, 5th ed., text revision. American Psychiatric Association; 2022.
  2. 2.Angstman KB, Rasmussen NH. Personality disorders: review and clinical application in daily practice. Am Fam Physician. 2011;84(11):1253-1260.
  3. 3.Zhan Yuen Wong N, Barnett P, Sheridan Rains L, et al. Evaluation of international guidance for the community treatment of ‘personality disorders’: a systematic review. PLoS One. 2023;18(3):e0264239.
  4. 4.Krueger RF, Hobbs KA. An overview of the DSM-5 alternative model of personality disorders. Psychopathology. 2020;53(3-4):126-132.
  5. 5.Waugh MH, Hopwood CJ, Krueger RF, et al. Psychological assessment with the DSM-5 alternative model for personality disorders: tradition and innovation. Prof Psychol Res Pr. 2017;48(2):79-89.
  6. 6.Żerdziński M, Burdzik M, Dębski P, et al. The impact of obsessive-compulsive personality disorder on obsessive-compulsive disorder: clinical outcomes in the context of bipolarity. Front Psychiatry. 2025;16:1532966.
  7. 7.Pinto A, Steinglass JE, Greene AL, et al. Capacity to delay reward differentiates obsessive-compulsive disorder and obsessive-compulsive personality disorder. Biol Psychiatry. 2014;75(8):653-659.
  8. 8.Grassi G, Pallanti S, Righi L, et al. Think twice: impulsivity and decision making in obsessive-compulsive disorder. J Behav Addict. 2015;4(4):263-272.
  9. 9.Clemente MJ, Martins Silva AS, Pozzolo Pedro MO, et al. A meta-analysis and meta-regression analysis of the global prevalence of obsessive-compulsive personality disorder. Heliyon. 2022;8(7):e09912.
  10. 10.Pinto A, Teller J, Wheaton MG. Obsessive-compulsive personality disorder: a review of symptomatology, impact on functioning, and treatment. Focus (Am Psychiatr Publ). 2022;20(4):389-396.
  11. 11.Ekselius L, von Knorring L. Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram. Int Clin Psychopharmacol. 1998;13(5):205-211.
  12. 12.Volavka J, Neziroglu F, Yaryura-Tobias JA. Clomipramine and imipramine in obsessive-compulsive disorder. Psychiatry Res. 1985;14(1):85-93.
  13. 13.Caligor E, Levy KN, Yeomans FE. Narcissistic personality disorder: diagnostic and clinical challenges. Am J Psychiatry. 2015;172(5):415-422.
  14. 14.Ronningstam E. Intersect between self-esteem and emotion regulation in narcissistic personality disorder—implications for alliance building and treatment. Borderline Personal Disord Emot Dysregul. 2017;4:3.
  15. 15.Russ E, Shedler J, Bradley R, et al. Refining the construct of narcissistic personality disorder: diagnostic criteria and subtypes. Am J Psychiatry. 2008;165(11):1473-1481.
  16. 16.Weinberg I, Ronningstam E. Narcissistic personality disorder: progress in understanding and treatment. Focus (Am Psychiatr Publ). 2022;20(4):368-377.
  17. 17.Leichsenring F, Heim N, Leweke F, et al. Borderline personality disorder: a review. JAMA. 2023;329(8):670-679.
  18. 18.Palmer BA, Pahwa M, Geske JR, et al. Self-report screening instruments differentiate bipolar disorder and borderline personality disorder. Brain Behav. 2021;11(7):e02201.
  19. 19.Mendez-Miller M, Naccarato J, Radico JA. Borderline personality disorder. Am Fam Physician. 2022;105(2):156-161.
  20. 20.May JM, Richardi TM, Barth KS. Dialectical behavior therapy as treatment for borderline personality disorder. Ment Health Clin. 2016;6(2):62-67.
  21. 21.Sinnaeve R, van den Bosch LMC, Hakkaart-van Roijen L, et al. Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial. Borderline Personal Disord Emot Dysregul. 2018;5:12.
  22. 22.Cohen D, Lau K, Lau S. Effect of psychotherapy on patients with borderline personality disorder. Am Fam Physician. 2022;106(4):381-382.
  23. 23.Chanen AM, Betts JK, Jackson H, et al. Effect of 3 forms of early intervention for young people with borderline personality disorder: the MOBY randomized clinical trial. JAMA Psychiatry. 2022;79(2):109-119.
  1. 1.World Health Organization. International Classification of Diseases 11th Revision (ICD-11). https://icd.who.int/en
  2. 2.Diagnostic and Statistical Manual of Mental Disorders, 5th ed., text revision. American Psychiatric Association; 2022.
  3. 3.Griswold KS, Del Regno PA, Berger RC. Recognition and differential diagnosis of psychosis in primary care. Am Fam Physician. 2015;91(12):856-863.
  4. 4.Maj M, van Os J, De Hert M, et al. The clinical characterization of the patient with primary psychosis aimed at personalization of management. World Psychiatry. 2021;20(1):4-33.
  5. 5.Arciniegas DB. Psychosis. Continuum (Minneap Minn). 2015;21(3 Behavioral Neurology and Neuropsychiatry):715-736.
  6. 6.Preda A, Blackman G. Assessment of psychosis. BMJ Best Practice. https://bestpractice.bmj.com/topics/en-us/1066
  7. 7.Berendsen S, van der Veen NM, van Tricht MJ, et al. Psychometric properties of the DSM-5 clinician-rated dimensions of psychosis symptom severity. Schizophr Res. 2020;216:416-421.
  8. 8.Boland R, Verduin ML, Ruiz P. Kaplan & Sadock’s Synopsis of Psychiatry, 12th ed. Lippincott Williams & Wilkins; 2021.
  9. 9.Lieberman JA, First MB. Psychotic disorders. N Engl J Med. 2018;379(3):270-280.
  10. 10.Marconi A, Di Forti M, Lewis CM, et al. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42(5):1262-1269.
  11. 11.Glasner-Edwards S, Mooney LJ. Methamphetamine psychosis: epidemiology and management. CNS Drugs. 2014;28(12):1115-1126.
  12. 12.Rahim MJ, Ghazali WS. Psychosis secondary to tuberculosis meningitis. BMJ Case Rep. 2016;2016:bcr2015213171.
  13. 13.Igata J, Okamoto N, Tesen H, et al. Human immunodeficiency virus-related neurocognitive disorder with hallucinations and delusions: a case report. Psychiatry Research Case Reports. 2024(3):100201.
  14. 14.Cheng JS, Hu JH, Chang MY, et al. Hepatitis C-associated late-onset schizophrenia: a nationwide, population-based cohort study. J Psychiatry Neurosci. 2021;46(6):E583-E591.
  15. 15.Faccioli J, Nardelli S, Gioia S, et al. Neurological and psychiatric effects of hepatitis C virus infection. World J Gastroenterol. 2021;27(29):4846-4861.
  16. 16.National CJD Research & Surveillance Unit. 32nd Annual Report 2023 Creutzfeldt-Jakob Disease Surveillance in the UK. https://cjd.ed.ac.uk/sites/default/files/2025-01/Latest%20NCJDRSU%20annual%20report%2C%20covering%20the%20period%201990-2023.pdf
  17. 17.Aarsland D. Epidemiology and pathophysiology of dementia-related psychosis. J Clin Psychiatry. 2020;81(5):AD19038BR1C.
  18. 18.Ffytche DH, Creese B, Politis M, et al. The psychosis spectrum in Parkinson disease. Nat Rev Neurol. 2017;13(2):81-95.
  19. 19.Nadkarni S, Arnedo V, Devinsky O. Psychosis in epilepsy patients. Epilepsia. 2007;48(suppl 9):17-19.
  20. 20.Kim JS, Hong SB, Park KW, et al. Psychotic symptoms in patients with major neurological diseases. J Clin Neurol. 2024;20(2):153-165.
  21. 21.Jurado-Flores M, Warda F, Mooradian A. Pathophysiology and clinical features of neuropsychiatric manifestations of thyroid disease. J Endocr Soc. 2022;6(2):bvab194.
  22. 22.Laurinaitienė K, Steiblienė V. Testosterone levels in patients with psychosis versus healthy subjects. Nordic Journal of Psychiatry. 2021;75(suppl 1):S19.
  23. 23.Baldaçara L, Ramos A, Castaldelli-Maia JM. Managing drug-induced psychosis. Int Rev Psychiatry. 2023;35(5-6):496-502.
  24. 24.Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543-546.
  25. 25.Gerhard T, Huybrechts K, Olfson M, et al. Comparative mortality risks of antipsychotic medications in community-dwelling older adults. Br J Psychiatry. 2014;205(1):44-51.
  26. 26.Stahl SM. Clozapine. Prescriber’s Guide: Stahl’s Essential Psychopharmacology. Cambridge University Press; 2024:191-200.
  27. 27.Rogers JP, Zandi MS, David AS. The diagnosis and treatment of catatonia. Clin Med (Lond). 2023;23(3):242-245.
  28. 28.Arnold MJ. Management of first-episode psychosis and schizophrenia: guidelines from the VA/DoD. Am Fam Physician. 2024;109(5):482-483.
  29. 29.Haidary HA, Padhy RK. Clozapine. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK535399/
  30. 30.Montastruc J-L, Lafaurie M, de Canecaude C, et al. Fatal adverse drug reactions: a worldwide perspective in the World Health Organization pharmacovigilance database. Br J Clin Pharmacol. 2021;87(11):4334-4340.
  31. 31.Walther S, Stegmayer K, Wilson JE, et al. Structure and neural mechanisms of catatonia. Lancet Psychiatry. 2019;6(7):610-619.
  32. 32.Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17(3):341-356.

Current edition

Hepatitis Overview

Hepatitis Overview

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.